BioSpace News Archive

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge

Neos Therapeutics, Inc., a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020, at 3:40 p.m. ET.

Krystal Biotech Inc. announced that Krish S. Krishnan, chairman and chief executive officer, will be presenting at the HC Wainwright 22nd Annual Global Investments Conference taking place September 14-16, 2020, as well as participating in a fireside chat at the Morgan Stanley Global Healthcare Conference taking place September 14-18, 2020.

Respiratory exerciser is a novel system that helps patients improve their lung function. This device improves the lung capacity and strengthens deep breathing effectively.

Needle holders are specialized hemostat tools used to hold the needles during surgical operations. Needle holders help in suturing by clamping the needle firmly.

Transparency Market Research has published a new report on the syphilis immunoassay diagnostics market for the forecast period of 2019 - 2027.

Stents are tubular type implants that are deployed most commonly to recover the shape of narrowed arterial segments. The stent scaffolds the artery open, improving blood flow.

Apros Therapeutics, Inc. announced that its Investigational New Drug application for a Phase 1 dose escalation trial of APR003, the company’s first-in-class orally-administered gastrointestinal- and liver-targeted TLR7 agonist development candidate, was cleared by the FDA.

Avivagen Inc. announces that it will be requesting approval from the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,774,992 common shares at $0.90 per share, which were originally issued on June 1, 2016.

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock in the United States.